Kathryn Hassell
Concepts (520)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anemia, Sickle Cell | 45 | 2025 | 253 | 7.110 |
Why?
| Water Pollutants, Chemical | 13 | 2022 | 197 | 2.310 |
Why?
| Antiphospholipid Syndrome | 5 | 2023 | 37 | 1.820 |
Why?
| Migraine Disorders | 2 | 2023 | 101 | 1.360 |
Why?
| Anticoagulants | 8 | 2021 | 637 | 1.250 |
Why?
| Perciformes | 5 | 2018 | 17 | 1.190 |
Why?
| Heparin | 5 | 2011 | 254 | 1.130 |
Why?
| Thrombocytopenia | 5 | 2014 | 189 | 1.130 |
Why?
| Fishes | 4 | 2021 | 94 | 1.070 |
Why?
| Antibodies, Antiphospholipid | 4 | 2023 | 26 | 1.060 |
Why?
| Estrogens | 3 | 2016 | 348 | 0.840 |
Why?
| Hydroxyurea | 5 | 2016 | 35 | 0.810 |
Why?
| Hypertension, Pulmonary | 11 | 2025 | 1897 | 0.780 |
Why?
| Pyridones | 2 | 2021 | 158 | 0.750 |
Why?
| Blood Transfusion | 7 | 2015 | 298 | 0.740 |
Why?
| Disorders of Sex Development | 2 | 2018 | 38 | 0.710 |
Why?
| Hirudins | 4 | 2011 | 53 | 0.690 |
Why?
| Fibrinolytic Agents | 2 | 2021 | 262 | 0.680 |
Why?
| Hemoglobins | 8 | 2021 | 339 | 0.680 |
Why?
| Testis | 2 | 2018 | 144 | 0.680 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2023 | 247 | 0.670 |
Why?
| Pyrazoles | 2 | 2021 | 403 | 0.660 |
Why?
| Caprylates | 1 | 2020 | 22 | 0.660 |
Why?
| Alkanesulfonic Acids | 1 | 2020 | 34 | 0.640 |
Why?
| Quality of Life | 6 | 2017 | 2695 | 0.610 |
Why?
| Oocytes | 2 | 2021 | 171 | 0.600 |
Why?
| Environmental Monitoring | 7 | 2022 | 309 | 0.590 |
Why?
| Fluorocarbons | 1 | 2020 | 109 | 0.580 |
Why?
| Neonatal Screening | 3 | 2020 | 163 | 0.560 |
Why?
| Hemopexin | 3 | 2025 | 27 | 0.550 |
Why?
| Cyprinidae | 1 | 2016 | 20 | 0.510 |
Why?
| Australia | 10 | 2022 | 243 | 0.510 |
Why?
| Pain | 5 | 2023 | 791 | 0.490 |
Why?
| Surveys and Questionnaires | 4 | 2017 | 5437 | 0.440 |
Why?
| Pain Measurement | 3 | 2017 | 510 | 0.430 |
Why?
| beta-Thalassemia | 2 | 2025 | 37 | 0.430 |
Why?
| Embryo, Nonmammalian | 2 | 2019 | 167 | 0.430 |
Why?
| Health Status Indicators | 1 | 2014 | 166 | 0.420 |
Why?
| Patient Outcome Assessment | 1 | 2014 | 127 | 0.420 |
Why?
| Adult | 41 | 2025 | 35634 | 0.410 |
Why?
| Tricuspid Valve Insufficiency | 3 | 2011 | 24 | 0.400 |
Why?
| Humans | 75 | 2025 | 129847 | 0.400 |
Why?
| Peptide Fragments | 4 | 2014 | 695 | 0.380 |
Why?
| Thrombosis | 4 | 2021 | 349 | 0.370 |
Why?
| Antithrombins | 2 | 2011 | 58 | 0.370 |
Why?
| Empirical Research | 1 | 2011 | 21 | 0.360 |
Why?
| Male | 47 | 2025 | 63759 | 0.350 |
Why?
| Nomograms | 1 | 2011 | 47 | 0.340 |
Why?
| Evidence-Based Medicine | 5 | 2017 | 716 | 0.340 |
Why?
| Censuses | 1 | 2010 | 27 | 0.330 |
Why?
| Animals | 28 | 2025 | 35409 | 0.330 |
Why?
| Female | 43 | 2025 | 68829 | 0.330 |
Why?
| Endocrine Disruptors | 3 | 2016 | 40 | 0.330 |
Why?
| Rivaroxaban | 2 | 2025 | 252 | 0.310 |
Why?
| Venous Thromboembolism | 2 | 2025 | 287 | 0.310 |
Why?
| Vitellogenins | 3 | 2016 | 10 | 0.310 |
Why?
| Young Adult | 18 | 2025 | 12467 | 0.310 |
Why?
| Heme | 3 | 2025 | 77 | 0.300 |
Why?
| Thrombophilia | 3 | 2007 | 81 | 0.300 |
Why?
| Health Priorities | 1 | 2009 | 34 | 0.300 |
Why?
| Carotid Artery, Internal, Dissection | 1 | 2008 | 13 | 0.290 |
Why?
| Stroke | 3 | 2021 | 1072 | 0.290 |
Why?
| Estuaries | 2 | 2021 | 3 | 0.280 |
Why?
| Self Care | 1 | 2010 | 368 | 0.280 |
Why?
| Middle Aged | 25 | 2025 | 31177 | 0.280 |
Why?
| Population Surveillance | 2 | 2010 | 439 | 0.280 |
Why?
| Gonads | 2 | 2018 | 23 | 0.280 |
Why?
| Heart Septal Defects, Atrial | 2 | 2005 | 54 | 0.280 |
Why?
| Hospitalists | 1 | 2011 | 233 | 0.270 |
Why?
| Sickle Cell Trait | 2 | 2018 | 13 | 0.270 |
Why?
| Nitric Oxide | 2 | 2018 | 896 | 0.270 |
Why?
| Fresh Water | 3 | 2020 | 52 | 0.270 |
Why?
| Biodiversity | 2 | 2021 | 380 | 0.260 |
Why?
| Haptoglobins | 2 | 2018 | 53 | 0.260 |
Why?
| Insecta | 1 | 2006 | 63 | 0.260 |
Why?
| Estradiol | 4 | 2016 | 494 | 0.260 |
Why?
| Kinetics | 2 | 2020 | 1645 | 0.260 |
Why?
| Phospholipids | 1 | 2008 | 216 | 0.260 |
Why?
| Environmental Pollutants | 2 | 2019 | 143 | 0.250 |
Why?
| Health Services Accessibility | 3 | 2016 | 903 | 0.250 |
Why?
| Patient Education as Topic | 1 | 2010 | 743 | 0.240 |
Why?
| Pregnancy Complications, Hematologic | 1 | 2005 | 20 | 0.240 |
Why?
| Hematopoietic Stem Cell Transplantation | 2 | 2025 | 577 | 0.240 |
Why?
| Adolescent | 20 | 2025 | 20451 | 0.240 |
Why?
| Iron | 3 | 2025 | 285 | 0.240 |
Why?
| Hospitalization | 4 | 2025 | 2079 | 0.240 |
Why?
| Estrone | 2 | 2016 | 37 | 0.230 |
Why?
| Spleen | 2 | 2025 | 508 | 0.230 |
Why?
| Factor Xa Inhibitors | 1 | 2025 | 170 | 0.210 |
Why?
| Cadmium | 2 | 2021 | 67 | 0.210 |
Why?
| Hemoglobinopathies | 1 | 2023 | 4 | 0.200 |
Why?
| Hemostasis | 2 | 2007 | 80 | 0.200 |
Why?
| Antisickling Agents | 2 | 2016 | 7 | 0.200 |
Why?
| Headache | 2 | 2023 | 151 | 0.200 |
Why?
| Wetlands | 2 | 2022 | 32 | 0.200 |
Why?
| Mass Screening | 1 | 2011 | 1192 | 0.200 |
Why?
| Child | 20 | 2024 | 20962 | 0.200 |
Why?
| Lung | 3 | 2025 | 3940 | 0.200 |
Why?
| Bays | 3 | 2017 | 6 | 0.200 |
Why?
| Psychometrics | 3 | 2016 | 701 | 0.190 |
Why?
| Severity of Illness Index | 3 | 2021 | 2739 | 0.190 |
Why?
| Pesticides | 1 | 2022 | 58 | 0.190 |
Why?
| Volatile Organic Compounds | 1 | 2023 | 57 | 0.190 |
Why?
| Recombinant Proteins | 4 | 2011 | 1311 | 0.190 |
Why?
| Hemolysis | 4 | 2021 | 199 | 0.190 |
Why?
| Arginine | 2 | 2015 | 262 | 0.180 |
Why?
| Metallothionein | 1 | 2021 | 25 | 0.180 |
Why?
| Arterial Occlusive Diseases | 1 | 2021 | 80 | 0.180 |
Why?
| alpha-Thalassemia | 1 | 2020 | 4 | 0.180 |
Why?
| Extracellular Vesicles | 1 | 2023 | 129 | 0.170 |
Why?
| Cyclooxygenase Inhibitors | 1 | 2021 | 80 | 0.170 |
Why?
| Acute Pain | 1 | 2021 | 48 | 0.170 |
Why?
| Fertility Preservation | 1 | 2021 | 39 | 0.170 |
Why?
| Desogestrel | 1 | 2021 | 45 | 0.170 |
Why?
| Aged | 11 | 2025 | 22107 | 0.170 |
Why?
| Proteome | 1 | 2025 | 440 | 0.170 |
Why?
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 66 | 0.170 |
Why?
| Infertility, Female | 1 | 2021 | 102 | 0.170 |
Why?
| Ecotoxicology | 1 | 2019 | 2 | 0.160 |
Why?
| Vascular Remodeling | 2 | 2019 | 192 | 0.160 |
Why?
| Partial Thromboplastin Time | 2 | 2011 | 52 | 0.160 |
Why?
| Polycyclic Aromatic Hydrocarbons | 2 | 2016 | 27 | 0.160 |
Why?
| Hemorrhage | 2 | 2021 | 680 | 0.160 |
Why?
| Clove Oil | 1 | 2019 | 1 | 0.160 |
Why?
| Eugenol | 1 | 2019 | 3 | 0.160 |
Why?
| Prospective Studies | 9 | 2025 | 7158 | 0.160 |
Why?
| Iron Chelating Agents | 2 | 2011 | 19 | 0.160 |
Why?
| Multiple Organ Failure | 2 | 2005 | 123 | 0.160 |
Why?
| Iron Overload | 2 | 2011 | 12 | 0.160 |
Why?
| Cyprinodontiformes | 1 | 2019 | 5 | 0.160 |
Why?
| Benzoates | 2 | 2011 | 41 | 0.160 |
Why?
| Liver | 3 | 2025 | 1839 | 0.160 |
Why?
| Exercise Tolerance | 2 | 2011 | 273 | 0.160 |
Why?
| Unrelated Donors | 1 | 2019 | 36 | 0.150 |
Why?
| Plastics | 1 | 2019 | 47 | 0.150 |
Why?
| Altitude | 3 | 2018 | 462 | 0.150 |
Why?
| Lipids | 2 | 2023 | 628 | 0.150 |
Why?
| Anesthetics | 1 | 2019 | 75 | 0.150 |
Why?
| Reproducibility of Results | 3 | 2017 | 3089 | 0.150 |
Why?
| Signal Transduction | 2 | 2013 | 4935 | 0.150 |
Why?
| Europe | 2 | 2016 | 363 | 0.140 |
Why?
| Triazoles | 2 | 2011 | 148 | 0.140 |
Why?
| Surgical Procedures, Operative | 2 | 2014 | 244 | 0.140 |
Why?
| Bone Marrow Transplantation | 1 | 2019 | 277 | 0.140 |
Why?
| Aspirin | 1 | 2021 | 380 | 0.140 |
Why?
| Treatment Outcome | 6 | 2025 | 10241 | 0.140 |
Why?
| Prevalence | 4 | 2024 | 2564 | 0.140 |
Why?
| Lipoproteins | 1 | 2018 | 172 | 0.140 |
Why?
| Climate Change | 1 | 2019 | 159 | 0.140 |
Why?
| Cohort Studies | 7 | 2018 | 5444 | 0.140 |
Why?
| Physical Exertion | 1 | 2018 | 210 | 0.140 |
Why?
| Factor Analysis, Statistical | 2 | 2016 | 284 | 0.140 |
Why?
| United States | 11 | 2023 | 13913 | 0.140 |
Why?
| Toll-Like Receptor 9 | 1 | 2017 | 31 | 0.130 |
Why?
| Platelet Factor 4 | 2 | 2008 | 34 | 0.130 |
Why?
| Zinc | 1 | 2020 | 286 | 0.130 |
Why?
| Pulmonary Artery | 4 | 2019 | 1097 | 0.130 |
Why?
| Renal Insufficiency, Chronic | 2 | 2019 | 567 | 0.130 |
Why?
| Hypoxia | 3 | 2019 | 1087 | 0.130 |
Why?
| Graft vs Host Disease | 1 | 2019 | 240 | 0.130 |
Why?
| Carps | 1 | 2016 | 2 | 0.130 |
Why?
| Anesthesia | 1 | 2019 | 172 | 0.130 |
Why?
| Osmeriformes | 1 | 2016 | 1 | 0.130 |
Why?
| Phenylketonurias | 1 | 2016 | 12 | 0.130 |
Why?
| Asia | 1 | 2016 | 58 | 0.130 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 756 | 0.130 |
Why?
| Principal Component Analysis | 2 | 2016 | 190 | 0.130 |
Why?
| Heart Diseases | 1 | 2019 | 352 | 0.130 |
Why?
| Sewage | 1 | 2016 | 29 | 0.130 |
Why?
| Retrospective Studies | 8 | 2021 | 14553 | 0.130 |
Why?
| Olfactory Perception | 1 | 2016 | 23 | 0.130 |
Why?
| Erythrocyte Transfusion | 2 | 2015 | 182 | 0.130 |
Why?
| Infant, Newborn | 5 | 2024 | 5772 | 0.130 |
Why?
| Metals, Heavy | 1 | 2016 | 29 | 0.120 |
Why?
| Rivers | 1 | 2016 | 58 | 0.120 |
Why?
| Macrophages | 2 | 2023 | 1489 | 0.120 |
Why?
| Trace Elements | 1 | 2016 | 49 | 0.120 |
Why?
| Copper | 1 | 2016 | 108 | 0.120 |
Why?
| Lung Diseases | 2 | 2019 | 743 | 0.120 |
Why?
| Thalassemia | 1 | 2015 | 6 | 0.120 |
Why?
| North America | 1 | 2016 | 294 | 0.120 |
Why?
| Splenic Infarction | 1 | 2014 | 1 | 0.120 |
Why?
| Fatigue | 1 | 2017 | 319 | 0.120 |
Why?
| Zebrafish | 1 | 2019 | 460 | 0.120 |
Why?
| Protein S Deficiency | 1 | 1994 | 7 | 0.110 |
Why?
| Dalteparin | 1 | 2014 | 10 | 0.110 |
Why?
| Blood Component Removal | 1 | 2014 | 26 | 0.110 |
Why?
| Complement Inactivator Proteins | 1 | 1994 | 41 | 0.110 |
Why?
| Quality of Health Care | 2 | 2016 | 610 | 0.110 |
Why?
| Transplantation Conditioning | 1 | 2015 | 166 | 0.110 |
Why?
| Blood Loss, Surgical | 1 | 2014 | 96 | 0.110 |
Why?
| Disease Models, Animal | 5 | 2025 | 4077 | 0.110 |
Why?
| Mice, Inbred C57BL | 5 | 2025 | 5468 | 0.110 |
Why?
| Postoperative Hemorrhage | 1 | 2014 | 88 | 0.110 |
Why?
| Thromboembolism | 1 | 2014 | 112 | 0.110 |
Why?
| Biomarkers | 5 | 2017 | 3971 | 0.110 |
Why?
| Leg Ulcer | 1 | 2013 | 6 | 0.100 |
Why?
| Larva | 2 | 2019 | 215 | 0.100 |
Why?
| Neoplasms | 2 | 2021 | 2454 | 0.100 |
Why?
| Blood Flow Velocity | 2 | 2014 | 406 | 0.100 |
Why?
| Ethinyl Estradiol | 1 | 2012 | 17 | 0.100 |
Why?
| Thrombin | 2 | 2023 | 147 | 0.100 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2013 | 97 | 0.100 |
Why?
| Venous Thrombosis | 2 | 2005 | 176 | 0.100 |
Why?
| Societies, Medical | 1 | 2017 | 759 | 0.100 |
Why?
| Patient Reported Outcome Measures | 1 | 2016 | 374 | 0.100 |
Why?
| Testosterone | 1 | 2016 | 372 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 836 | 0.100 |
Why?
| Sex Factors | 3 | 2019 | 1973 | 0.100 |
Why?
| Chronic Pain | 1 | 2017 | 253 | 0.100 |
Why?
| Preoperative Care | 2 | 2005 | 337 | 0.100 |
Why?
| Ambulatory Care | 1 | 2016 | 509 | 0.100 |
Why?
| Analgesics, Opioid | 3 | 2023 | 925 | 0.100 |
Why?
| Endothelium, Vascular | 1 | 2018 | 902 | 0.100 |
Why?
| Child, Preschool | 10 | 2024 | 10522 | 0.100 |
Why?
| Practice Guidelines as Topic | 3 | 2015 | 1514 | 0.090 |
Why?
| Hemoglobin SC Disease | 3 | 1998 | 13 | 0.090 |
Why?
| Prostheses and Implants | 2 | 2021 | 135 | 0.090 |
Why?
| Mortality | 2 | 2012 | 308 | 0.090 |
Why?
| Hydrogen-Ion Concentration | 1 | 2012 | 541 | 0.090 |
Why?
| Pipecolic Acids | 1 | 2011 | 25 | 0.090 |
Why?
| Creatinine | 2 | 2014 | 490 | 0.090 |
Why?
| Transfusion Reaction | 1 | 2011 | 43 | 0.090 |
Why?
| Mice | 6 | 2025 | 16983 | 0.090 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2013 | 541 | 0.090 |
Why?
| Hemofiltration | 1 | 2010 | 30 | 0.090 |
Why?
| Sulfones | 1 | 2011 | 108 | 0.090 |
Why?
| Disease Progression | 4 | 2023 | 2628 | 0.080 |
Why?
| Awareness | 1 | 2010 | 99 | 0.080 |
Why?
| Disease Management | 2 | 2011 | 592 | 0.080 |
Why?
| Vasodilator Agents | 1 | 2011 | 326 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 2 | 2016 | 2016 | 0.080 |
Why?
| Piperazines | 1 | 2011 | 339 | 0.080 |
Why?
| Aged, 80 and over | 4 | 2025 | 7066 | 0.070 |
Why?
| Career Choice | 1 | 2010 | 206 | 0.070 |
Why?
| Echocardiography | 1 | 2011 | 636 | 0.070 |
Why?
| Pregnancy | 3 | 2005 | 6423 | 0.070 |
Why?
| Drug Utilization Review | 1 | 2008 | 57 | 0.070 |
Why?
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 84 | 0.070 |
Why?
| Anaerobiosis | 1 | 2008 | 57 | 0.070 |
Why?
| Software | 1 | 2013 | 608 | 0.070 |
Why?
| Seawater | 1 | 2008 | 26 | 0.070 |
Why?
| Depression | 1 | 2017 | 1323 | 0.070 |
Why?
| Ventricular Dysfunction, Left | 1 | 2011 | 385 | 0.070 |
Why?
| Endothelial Cells | 1 | 2013 | 749 | 0.070 |
Why?
| Kidney Function Tests | 1 | 2008 | 152 | 0.070 |
Why?
| Cost of Illness | 1 | 2010 | 277 | 0.070 |
Why?
| Oxidation-Reduction | 3 | 2018 | 1031 | 0.070 |
Why?
| Community Participation | 1 | 2009 | 125 | 0.070 |
Why?
| Metabolomics | 1 | 2013 | 652 | 0.070 |
Why?
| Proteomics | 2 | 2025 | 1058 | 0.070 |
Why?
| Body Size | 1 | 2008 | 103 | 0.070 |
Why?
| Lipid Peroxidation | 2 | 2018 | 152 | 0.070 |
Why?
| Histocompatibility Testing | 2 | 2019 | 121 | 0.070 |
Why?
| Registries | 2 | 2023 | 1903 | 0.070 |
Why?
| Double-Blind Method | 3 | 2023 | 1877 | 0.070 |
Why?
| Deferoxamine | 1 | 2007 | 20 | 0.070 |
Why?
| Sulfonamides | 1 | 2011 | 497 | 0.070 |
Why?
| Environmental Exposure | 3 | 2019 | 463 | 0.070 |
Why?
| Chironomidae | 1 | 2006 | 1 | 0.070 |
Why?
| Algorithms | 1 | 2014 | 1617 | 0.070 |
Why?
| Age Factors | 2 | 2014 | 3161 | 0.070 |
Why?
| Acute Kidney Injury | 2 | 2010 | 791 | 0.070 |
Why?
| Rhabdomyolysis | 2 | 2018 | 22 | 0.070 |
Why?
| Social Support | 1 | 2010 | 587 | 0.060 |
Why?
| Urbanization | 2 | 2016 | 27 | 0.060 |
Why?
| Time Factors | 3 | 2019 | 6550 | 0.060 |
Why?
| Fibrinolysis | 2 | 1998 | 137 | 0.060 |
Why?
| Sodium Chloride | 1 | 2006 | 138 | 0.060 |
Why?
| Body Weight | 2 | 2021 | 947 | 0.060 |
Why?
| Coronary Angiography | 1 | 2008 | 306 | 0.060 |
Why?
| Emergency Service, Hospital | 1 | 2016 | 1920 | 0.060 |
Why?
| Dermatan Sulfate | 1 | 2005 | 3 | 0.060 |
Why?
| Species Specificity | 1 | 2006 | 568 | 0.060 |
Why?
| Health Care Surveys | 2 | 2020 | 558 | 0.060 |
Why?
| Factor V | 1 | 2005 | 18 | 0.060 |
Why?
| Captopril | 1 | 2005 | 10 | 0.060 |
Why?
| Heparitin Sulfate | 1 | 2005 | 42 | 0.060 |
Why?
| Ecosystem | 2 | 2021 | 561 | 0.060 |
Why?
| Chondroitin Sulfates | 1 | 2005 | 35 | 0.060 |
Why?
| Survival Analysis | 1 | 2008 | 1271 | 0.060 |
Why?
| Infant Mortality | 1 | 2005 | 106 | 0.060 |
Why?
| Heme Oxygenase-1 | 1 | 2025 | 62 | 0.060 |
Why?
| Angina, Unstable | 1 | 2005 | 76 | 0.060 |
Why?
| Public Health Surveillance | 1 | 2024 | 68 | 0.060 |
Why?
| Needs Assessment | 1 | 2007 | 357 | 0.060 |
Why?
| Polysaccharides | 1 | 2005 | 86 | 0.060 |
Why?
| Standard of Care | 1 | 2025 | 71 | 0.060 |
Why?
| Risk | 2 | 2005 | 860 | 0.060 |
Why?
| Chest Pain | 1 | 2005 | 88 | 0.060 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2005 | 78 | 0.060 |
Why?
| Immunoglobulin G | 1 | 2008 | 851 | 0.060 |
Why?
| Blood Component Transfusion | 1 | 2005 | 83 | 0.060 |
Why?
| Practice Patterns, Physicians' | 2 | 2013 | 1274 | 0.050 |
Why?
| Aerosols | 1 | 2025 | 171 | 0.050 |
Why?
| Follow-Up Studies | 3 | 2021 | 4896 | 0.050 |
Why?
| Drug Combinations | 1 | 2005 | 331 | 0.050 |
Why?
| Acute Disease | 2 | 2019 | 980 | 0.050 |
Why?
| Alabama | 1 | 2023 | 33 | 0.050 |
Why?
| Risk Factors | 5 | 2018 | 9801 | 0.050 |
Why?
| Syndrome | 2 | 2014 | 338 | 0.050 |
Why?
| Oxygen | 1 | 2008 | 916 | 0.050 |
Why?
| Simazine | 1 | 2022 | 2 | 0.050 |
Why?
| Glycolysis | 1 | 2025 | 314 | 0.050 |
Why?
| E-Selectin | 1 | 2023 | 55 | 0.050 |
Why?
| Antibodies | 1 | 2005 | 399 | 0.050 |
Why?
| Renal Insufficiency | 1 | 2005 | 149 | 0.050 |
Why?
| Medical Records | 1 | 2023 | 171 | 0.050 |
Why?
| Education, Medical, Graduate | 1 | 2007 | 443 | 0.050 |
Why?
| Healthcare Disparities | 1 | 2009 | 580 | 0.050 |
Why?
| Substance-Related Disorders | 1 | 2011 | 1023 | 0.050 |
Why?
| United Kingdom | 2 | 2014 | 258 | 0.050 |
Why?
| Coronary Artery Disease | 1 | 2008 | 680 | 0.050 |
Why?
| Agriculture | 1 | 2022 | 93 | 0.050 |
Why?
| P-Selectin | 1 | 2021 | 27 | 0.050 |
Why?
| Data Collection | 1 | 2024 | 653 | 0.050 |
Why?
| Incidence | 2 | 2021 | 2646 | 0.050 |
Why?
| Colorado | 3 | 2024 | 4410 | 0.050 |
Why?
| Dietary Exposure | 1 | 2021 | 5 | 0.040 |
Why?
| Oocyte Retrieval | 1 | 2021 | 10 | 0.040 |
Why?
| Vitrification | 1 | 2021 | 6 | 0.040 |
Why?
| Blood Pressure | 3 | 2018 | 1736 | 0.040 |
Why?
| Ovarian Hyperstimulation Syndrome | 1 | 2021 | 7 | 0.040 |
Why?
| Oogenesis | 1 | 2021 | 20 | 0.040 |
Why?
| Ovulation Induction | 1 | 2021 | 52 | 0.040 |
Why?
| Phylogeography | 1 | 2021 | 48 | 0.040 |
Why?
| von Willebrand Factor | 2 | 1998 | 71 | 0.040 |
Why?
| Anti-Mullerian Hormone | 1 | 2021 | 51 | 0.040 |
Why?
| Leukocytes, Mononuclear | 1 | 2023 | 546 | 0.040 |
Why?
| Monocytes | 1 | 2023 | 554 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2016 | 1501 | 0.040 |
Why?
| Cardiac Catheterization | 1 | 2004 | 520 | 0.040 |
Why?
| Luteinizing Hormone | 1 | 2021 | 178 | 0.040 |
Why?
| Cryopreservation | 1 | 2021 | 94 | 0.040 |
Why?
| Metals | 1 | 2021 | 123 | 0.040 |
Why?
| Australasia | 1 | 2019 | 2 | 0.040 |
Why?
| HIV Infections | 1 | 1994 | 2730 | 0.040 |
Why?
| Follicle Stimulating Hormone | 1 | 2021 | 237 | 0.040 |
Why?
| Case-Control Studies | 2 | 2018 | 3384 | 0.040 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2021 | 204 | 0.040 |
Why?
| Gadolinium | 1 | 2019 | 78 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2005 | 1368 | 0.040 |
Why?
| Rats | 2 | 2019 | 5487 | 0.040 |
Why?
| Cell Line | 2 | 2015 | 2780 | 0.040 |
Why?
| Tissue Distribution | 1 | 2019 | 316 | 0.040 |
Why?
| Proteinuria | 1 | 2018 | 91 | 0.040 |
Why?
| Allografts | 1 | 2019 | 137 | 0.040 |
Why?
| Endothelins | 1 | 2018 | 62 | 0.040 |
Why?
| Oxidative Stress | 1 | 2025 | 1264 | 0.040 |
Why?
| Guinea Pigs | 1 | 2018 | 157 | 0.040 |
Why?
| Thrombomodulin | 1 | 1998 | 10 | 0.040 |
Why?
| Body Height | 1 | 2018 | 192 | 0.040 |
Why?
| Victoria | 1 | 2017 | 16 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2019 | 647 | 0.030 |
Why?
| Pilot Projects | 2 | 2016 | 1597 | 0.030 |
Why?
| Public Health Practice | 1 | 2017 | 64 | 0.030 |
Why?
| Anemia, Hemolytic | 1 | 2017 | 16 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2011 | 766 | 0.030 |
Why?
| Cytochrome P-450 CYP1A1 | 1 | 2016 | 9 | 0.030 |
Why?
| Proteins | 1 | 2023 | 944 | 0.030 |
Why?
| Fish Proteins | 1 | 2016 | 10 | 0.030 |
Why?
| Acclimatization | 1 | 2018 | 166 | 0.030 |
Why?
| Intraoperative Complications | 1 | 1998 | 129 | 0.030 |
Why?
| Bile | 1 | 2016 | 35 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 1005 | 0.030 |
Why?
| Public-Private Sector Partnerships | 1 | 2017 | 42 | 0.030 |
Why?
| Polychlorinated Biphenyls | 1 | 2016 | 9 | 0.030 |
Why?
| Cross-Sectional Studies | 3 | 2016 | 5085 | 0.030 |
Why?
| Blood Coagulation Factors | 1 | 1996 | 53 | 0.030 |
Why?
| Genetic Markers | 1 | 2017 | 334 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2008 | 3397 | 0.030 |
Why?
| RNA, Messenger | 2 | 2013 | 2703 | 0.030 |
Why?
| Community Health Services | 1 | 2017 | 229 | 0.030 |
Why?
| United States Food and Drug Administration | 1 | 2017 | 205 | 0.030 |
Why?
| Mononuclear Phagocyte System | 1 | 1995 | 11 | 0.030 |
Why?
| Erythrocyte Count | 1 | 1995 | 19 | 0.030 |
Why?
| Erythrocytes, Abnormal | 1 | 1995 | 11 | 0.030 |
Why?
| Silicon Dioxide | 1 | 2016 | 109 | 0.030 |
Why?
| Continuity of Patient Care | 1 | 2017 | 277 | 0.030 |
Why?
| Arginase | 1 | 2015 | 32 | 0.030 |
Why?
| Odorants | 1 | 2016 | 150 | 0.030 |
Why?
| Vitamin B 6 Deficiency | 1 | 1994 | 5 | 0.030 |
Why?
| Excitatory Amino Acids | 1 | 1994 | 7 | 0.030 |
Why?
| Amino Acids, Sulfur | 1 | 1994 | 7 | 0.030 |
Why?
| Cysteic Acid | 1 | 1994 | 1 | 0.030 |
Why?
| beta 2-Glycoprotein I | 1 | 1994 | 4 | 0.030 |
Why?
| Blood Coagulation | 1 | 1996 | 239 | 0.030 |
Why?
| Lupus Coagulation Inhibitor | 1 | 1994 | 5 | 0.030 |
Why?
| Siblings | 1 | 2015 | 216 | 0.030 |
Why?
| Blood Cell Count | 1 | 2014 | 53 | 0.030 |
Why?
| Consensus Development Conferences as Topic | 1 | 2014 | 27 | 0.030 |
Why?
| Antibodies, Anticardiolipin | 1 | 1994 | 8 | 0.030 |
Why?
| Blood Platelets | 1 | 1998 | 386 | 0.030 |
Why?
| Health Policy | 1 | 2017 | 354 | 0.030 |
Why?
| Hematocrit | 1 | 2014 | 93 | 0.030 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2015 | 135 | 0.030 |
Why?
| Automation | 1 | 2014 | 81 | 0.030 |
Why?
| Interview, Psychological | 1 | 2014 | 93 | 0.030 |
Why?
| Echocardiography, Doppler | 1 | 2015 | 108 | 0.030 |
Why?
| Folic Acid Deficiency | 1 | 1994 | 48 | 0.030 |
Why?
| Survival Rate | 1 | 2019 | 1872 | 0.030 |
Why?
| Penicillins | 1 | 2014 | 57 | 0.030 |
Why?
| Hypertrophy, Right Ventricular | 1 | 2015 | 145 | 0.030 |
Why?
| Ferritins | 1 | 2014 | 58 | 0.030 |
Why?
| Vitamin B 12 Deficiency | 1 | 1994 | 78 | 0.030 |
Why?
| DNA Damage | 1 | 2016 | 383 | 0.030 |
Why?
| Hematologic Tests | 1 | 1994 | 22 | 0.030 |
Why?
| Muscle, Smooth, Vascular | 1 | 2017 | 444 | 0.030 |
Why?
| Natriuretic Peptide, Brain | 1 | 2014 | 99 | 0.030 |
Why?
| Homocysteine | 1 | 1994 | 152 | 0.030 |
Why?
| Smegmamorpha | 1 | 2013 | 2 | 0.030 |
Why?
| Mood Disorders | 1 | 2014 | 121 | 0.030 |
Why?
| Folic Acid | 1 | 1995 | 182 | 0.030 |
Why?
| Antibiotic Prophylaxis | 1 | 2014 | 102 | 0.030 |
Why?
| Carrier Proteins | 2 | 1995 | 741 | 0.030 |
Why?
| Catalase | 1 | 2013 | 128 | 0.030 |
Why?
| Cell Membrane Permeability | 1 | 2013 | 82 | 0.030 |
Why?
| Vascular Resistance | 1 | 2015 | 371 | 0.030 |
Why?
| Abdominal Pain | 1 | 2014 | 143 | 0.030 |
Why?
| Hemoglobin, Sickle | 1 | 2013 | 18 | 0.030 |
Why?
| Brain Diseases | 1 | 1994 | 134 | 0.030 |
Why?
| Liver Failure, Acute | 1 | 1994 | 66 | 0.030 |
Why?
| Permeability | 1 | 2013 | 158 | 0.030 |
Why?
| Clinical Protocols | 1 | 2014 | 254 | 0.030 |
Why?
| Cysteine | 1 | 1994 | 195 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 30 | 0.030 |
Why?
| Interleukin-6 | 1 | 2017 | 724 | 0.030 |
Why?
| Perioperative Care | 1 | 2014 | 166 | 0.030 |
Why?
| Employment | 1 | 2014 | 167 | 0.030 |
Why?
| Equipment Design | 1 | 2014 | 514 | 0.030 |
Why?
| Erythrocyte Indices | 1 | 2012 | 27 | 0.030 |
Why?
| Receptors, Cell Surface | 1 | 1995 | 381 | 0.030 |
Why?
| Behavior, Animal | 1 | 2016 | 496 | 0.020 |
Why?
| Glycoproteins | 1 | 1994 | 338 | 0.020 |
Why?
| Vascular Diseases | 1 | 2015 | 240 | 0.020 |
Why?
| Choline | 1 | 2013 | 122 | 0.020 |
Why?
| Social Behavior | 1 | 2014 | 286 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 851 | 0.020 |
Why?
| Inflammation | 1 | 2023 | 2748 | 0.020 |
Why?
| Wounds and Injuries | 1 | 2018 | 711 | 0.020 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2008 | 3630 | 0.020 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 235 | 0.020 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 274 | 0.020 |
Why?
| Macrophages, Alveolar | 1 | 2015 | 389 | 0.020 |
Why?
| Cell-Derived Microparticles | 1 | 2012 | 68 | 0.020 |
Why?
| Physician-Patient Relations | 1 | 2016 | 542 | 0.020 |
Why?
| Public Health | 1 | 2016 | 487 | 0.020 |
Why?
| Toll-Like Receptor 4 | 1 | 2013 | 264 | 0.020 |
Why?
| Health Status | 1 | 2016 | 758 | 0.020 |
Why?
| Physical Therapy Modalities | 1 | 2014 | 296 | 0.020 |
Why?
| Superoxide Dismutase | 1 | 2013 | 342 | 0.020 |
Why?
| Sildenafil Citrate | 1 | 2011 | 59 | 0.020 |
Why?
| Proportional Hazards Models | 1 | 2014 | 1199 | 0.020 |
Why?
| Homozygote | 1 | 2011 | 195 | 0.020 |
Why?
| Familial Primary Pulmonary Hypertension | 1 | 2011 | 199 | 0.020 |
Why?
| Hemodynamics | 2 | 2011 | 1094 | 0.020 |
Why?
| Up-Regulation | 1 | 2013 | 836 | 0.020 |
Why?
| Communication | 1 | 2016 | 847 | 0.020 |
Why?
| Respiratory Insufficiency | 1 | 1994 | 313 | 0.020 |
Why?
| Purines | 1 | 2011 | 172 | 0.020 |
Why?
| Mice, Knockout | 1 | 2017 | 2888 | 0.020 |
Why?
| Metabolome | 1 | 2013 | 339 | 0.020 |
Why?
| Walking | 1 | 2014 | 500 | 0.020 |
Why?
| NF-kappa B | 1 | 2013 | 666 | 0.020 |
Why?
| Pediatrics | 1 | 2017 | 1074 | 0.020 |
Why?
| Erythrocytes | 1 | 1995 | 673 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2015 | 2403 | 0.020 |
Why?
| Cell Proliferation | 1 | 2017 | 2378 | 0.020 |
Why?
| Gastrointestinal Diseases | 1 | 2011 | 198 | 0.020 |
Why?
| Databases, Factual | 1 | 2014 | 1269 | 0.020 |
Why?
| Pneumonia | 1 | 2015 | 619 | 0.020 |
Why?
| Sepsis | 1 | 1995 | 576 | 0.020 |
Why?
| Exercise Test | 1 | 2011 | 614 | 0.020 |
Why?
| Gene Expression | 1 | 2013 | 1465 | 0.020 |
Why?
| Genotype | 1 | 2013 | 1829 | 0.020 |
Why?
| Comorbidity | 1 | 2012 | 1551 | 0.020 |
Why?
| Infant | 3 | 2014 | 9018 | 0.020 |
Why?
| Chelation Therapy | 1 | 2007 | 11 | 0.020 |
Why?
| Postoperative Complications | 1 | 2018 | 2481 | 0.020 |
Why?
| Health Personnel | 1 | 2013 | 658 | 0.020 |
Why?
| Cardiovascular Diseases | 1 | 2018 | 2008 | 0.020 |
Why?
| Calcinosis | 1 | 2008 | 233 | 0.020 |
Why?
| Diabetic Angiopathies | 1 | 2008 | 261 | 0.020 |
Why?
| Alanine Transaminase | 1 | 2007 | 154 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2016 | 1644 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2011 | 1951 | 0.020 |
Why?
| Health Services | 1 | 2007 | 99 | 0.020 |
Why?
| Mental Disorders | 1 | 1994 | 1035 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 1724 | 0.020 |
Why?
| Critical Illness | 1 | 2010 | 759 | 0.010 |
Why?
| Program Development | 1 | 2007 | 355 | 0.010 |
Why?
| Administration, Oral | 1 | 2007 | 787 | 0.010 |
Why?
| Gas Chromatography-Mass Spectrometry | 2 | 1995 | 131 | 0.010 |
Why?
| Isotope Labeling | 2 | 1995 | 74 | 0.010 |
Why?
| Academic Medical Centers | 1 | 2007 | 483 | 0.010 |
Why?
| Logistic Models | 1 | 2008 | 1989 | 0.010 |
Why?
| Respiratory Tract Infections | 1 | 2007 | 376 | 0.010 |
Why?
| Referral and Consultation | 1 | 2007 | 735 | 0.010 |
Why?
| Attitude of Health Personnel | 1 | 2008 | 1106 | 0.010 |
Why?
| Insulin Resistance | 1 | 2008 | 1168 | 0.010 |
Why?
| Physicians | 1 | 2008 | 875 | 0.010 |
Why?
| Delivery of Health Care | 1 | 2007 | 900 | 0.010 |
Why?
| Liver Function Tests | 1 | 1996 | 112 | 0.010 |
Why?
| Respiration | 1 | 1996 | 193 | 0.010 |
Why?
| Folate Receptors, GPI-Anchored | 1 | 1995 | 5 | 0.010 |
Why?
| Vacuoles | 1 | 1995 | 36 | 0.010 |
Why?
| 4-Aminobenzoic Acid | 1 | 1995 | 7 | 0.010 |
Why?
| Lactobacillus | 1 | 1995 | 26 | 0.010 |
Why?
| Radionuclide Imaging | 1 | 1995 | 122 | 0.010 |
Why?
| Reference Standards | 1 | 1995 | 176 | 0.010 |
Why?
| Carbon Isotopes | 1 | 1995 | 127 | 0.010 |
Why?
| Aspartic Acid | 1 | 1994 | 80 | 0.010 |
Why?
| Neurotransmitter Agents | 1 | 1994 | 81 | 0.010 |
Why?
| Deuterium | 1 | 1994 | 87 | 0.010 |
Why?
| Disease Susceptibility | 1 | 1995 | 334 | 0.010 |
Why?
| Reference Values | 1 | 1994 | 796 | 0.010 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 1994 | 210 | 0.010 |
Why?
| Cattle | 1 | 1995 | 978 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 1995 | 1847 | 0.010 |
Why?
| Brain | 1 | 1994 | 2677 | 0.000 |
Why?
|
|
Hassell's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|